New Arabica coffee compounds may slow post-meal blood sugar spikes, lab study suggests
Latest news on WhatsApp أجدد الأخبار على واتسابPublished in Beverage Plant Research, the researchers reported isolating three newly described molecules, named caffaldehydes A, B and C. In lab tests, the compounds inhibited alpha-glucosidase, an enzyme involved in breaking down carbohydrates during digestion. This is the same therapeutic target as acarbose, a drug used to help slow glucose release into the bloodstream after meals.
The team used a multi-step extraction and screening approach, alongside techniques such as 1D NMR and LC-MS/MS molecular networking, to detect even low-abundance bioactive compounds. They said the findings could support future development of “functional foods” or nutraceutical ingredients, while emphasizing the current evidence is laboratory-based rather than clinical proof in humans.
More broadly, large evidence reviews have linked moderate coffee intake with a lower risk of developing type 2 diabetes in observational research, though causality is not established. Separately, an Oxford-led systematic review in The BMJ reported that benefits from weight-loss medications, including GLP-1 drugs, tend to diminish after discontinuation, with many people regaining weight within roughly two years.
